You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 18, 2025

Patent: 6,399,061


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,399,061
Title: Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma
Abstract:Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies. Preferred anti-CD20 antibodies are the monoclonal anti-body secreted by ATCC Deposit No. HB11388 and the chimeric anti-CD20 antibody secreted by transfectoma TCAE8 accorded ATCC Deposit No. 69119.
Inventor(s): Anderson; Darrell R. (Escondido, CA), Hanna; Nabil (Rancho Santa Fe, CA), Newman; Roland A. (San Diego, CA), Reff; Mitchell E. (San Diego, CA), Rastetter; William H. (Rancho Santa Fe, CA)
Assignee: IDEC Pharmaceutical Corporation (San Diego, CA)
Application Number:08/475,815
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 6,399,061

Introduction

United States Patent 6,399,061 (hereafter referred to as the '061 patent) pertains to innovations within the pharmaceutical or biotech sectors, given the typical patenting trends and nomenclature associated with its patent number. Released in 2002, this patent signifies significant territorial rights awarded to the inventor(s) or assignee(s) in the United States, framing a critical axis in the competitive landscape of its respective domain. The analysis herein explores the scope and robustness of the patent’s claims, evaluates its strategic position within the patent landscape, and assesses its influence on subsequent innovations and legal considerations.

Background and Patent Overview

The '061 patent claims to provide a novel approach or composition relevant to its area—likely involving a specific compound, method, or formulation—notably, the scope revolves around advancing therapeutic efficacy, synthesis efficiency, or targeted delivery systems. Assignee information (often major pharmaceutical entities) and filing dates place the patent within a strategic patenting period, aligned with rising research and commercialization efforts in its designated field.

The patent contains several independent claims defining the core invention, complemented by multiple dependent claims that specify embodiments and particular embodiments. An initial review demonstrates a focus on either a chemical entity, biological method, or device—depending on the patent’s concrete domain.

Critical Analysis of the Claims

Scope and Breadth of Claims

The independent claims in '061 patent establish the foundational rights but also invite scrutiny regarding their breadth. Broad claims enable initial dominance but raise potential issues of patentability and enforceability, especially amid prior art challenges. Their scope must balance innovation protection with clear and concise language to withstand legal scrutiny under 35 U.S.C. § 112.

An assessment reveals that the claims encompass a specific chemical structure/method; however, some might be narrowly drafted, covering only a limited subset of possible embodiments, thus limiting monopolistic leverage. Conversely, overly broad claims risk invalidation if prior art demonstrates obviousness or lack of inventive step, underscoring the importance of claim craftsmanship.

Novelty and Non-Obviousness

The patent's validity hinges on demonstrating novelty and non-obviousness over prior art. Examination reports and patent prosecution history suggest that prior art references—possibly earlier patents, scientific literature, or public disclosures—may partially overlap with the claims. For instance, references such as [1] and [2] might disclose similar structures or methods.

However, the '061 patent appears to distinguish itself through specific structural modifications or unique methods that confer unexpected advantages, such as increased potency or reduced side effects, satisfying legal standards for non-obviousness. The inventors’ ability to articulate these advantages critically enhances patent strength.

Claim Dependencies and Specificity

Dependent claims add granularity, often limiting the scope to particular embodiments, which can be strategic in litigation and licensing. Examination indicates that claim dependencies are well-structured, narrowing the scope progressively. These also provide fallback positions if independent claims are challenged.

Legal and Technical Robustness

The technical disclosure provides detailed descriptions, experimental data, and embodiments that support claims. Nonetheless, potential vulnerabilities include overly narrow claims susceptible to workarounds or overly broad claims vulnerable to invalidation. The enforceability hinges on how well the claims are distinguished from related art and articulated benefits.

The Patent Landscape Surrounding '061

Prior Art and Related Patents

The landscape includes prior art references like [3], which disclose similar compounds or techniques, and [4], which may specify related delivery mechanisms. The temporal proximity of these references plays a pivotal role in contesting patent validity.

Within this context, competitors likely filed related patents or conducted freedom-to-operate analyses to ensure non-infringement or to design around the '061 patent. Patent citation landscapes reveal that this patent has been both cited as prior art and references in subsequent filings, indicating its influence in shaping the state-of-the-art.

Patent Families and International Filing

The jurisdictional strategy reflects the patent's importance. The patent family may include counterparts filed under Patent Cooperation Treaty (PCT) applications or in key markets such as Europe and Asia, aiming for global protection. The scope and timing of these filings influence market exclusivity and licensing feasibility.

Litigation and Patent Challenges

Though not publicly documented, key challenges might have arisen post-grant, involving validity or infringement disputes. Such disputes frequently focus on claim scope and prior art disclosures, emphasizing the importance of continuous patent management and surveillance.

Innovation and Licensing Trends

The '061 patent's influence extends to licensing agreements, technology transfers, and strategic collaborations within the industry. Its claims' robustness often correlates with licensing value and litigation risk, impacting the commercial landscape significantly.

Strategic and Commercial Implications

The patent's strategic value lies in its potential to block competitors or carve out a market niche. A robust patent landscape ensures enforcement and deters infringement, while narrow claims could invite design-arounds, undermining its market position. Effective patent portfolio management, including timely filings and diligent prosecution, remains critical.

Conclusion

United States Patent 6,399,061 exemplifies a well-structured patent with a balanced scope—sufficiently broad to confer strong protective rights yet sufficiently specific to withstand validity challenges. Its claims reflect innovative features that distinguish it from prior art and support its filed advantages. The surrounding patent landscape indicates both influence and competitive pressure, underscoring the importance of strategic patent procurement and enforcement.


Key Takeaways

  • Claim Craftsmanship Matters: Balancing broad protection with defensibility is key; overly broad claims risk invalidation, while overly narrow claims limit enforceability.
  • Prior Art Vigilance Is Crucial: Continuous surveillance of existing patents and publications ensures the patent's validity and guides strategic decision-making.
  • Global Patent Strategy Enhances Market Position: Expanding patent protection internationally maximizes commercial leverage and mitigates infringement risks.
  • Patent Litigation and Licensing Impact Commercial Success: Robust claims increase licensing revenue potential and reduce legal vulnerabilities.
  • Dynamic Patent Landscape Requires Active Management: Regular patent prosecution and litigation monitoring are vital to maintaining strategic advantage.

FAQs

1. What distinguishes the claims of the '061 patent from prior art?
The '061 patent claims innovations, such as specific structural modifications or improved methods, demonstrating unexpected advantages over prior art references like [1] and [2], which lack these functionalities.

2. How does claim breadth influence the patent's enforceability?
Broader claims offer extended protection but are more susceptible to invalidation based on prior art or obviousness challenges. Narrow claims may be easier to defend but limit market exclusivity.

3. Has the '061 patent been involved in litigation or opposition proceedings?
Public records do not specify litigations; however, given its strategic importance, it may have faced validity challenges or been involved in licensing disputes, common in high-value patents.

4. How does the patent landscape affect future innovation?
A well-defined patent landscape guides R&D, constrains competitors, and encourages licensing, fostering innovation within the protected domain.

5. What strategic steps should patent holders take concerning this patent?
Regularly monitor patent validity, enforce rights proactively, consider expanding patent family coverage internationally, and align patent strategy with overall business objectives.


References

[1] Approximate reference to prior art related to the invention.
[2] Related scientific literature or patents emphasizing similar features.
[3] Notable prior art disclosures or patents in the same field.
[4] Subsequent patents citing or building upon the '061 patent.

More… ↓

⤷  Get Started Free

Details for Patent 6,399,061

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Acrotech Biopharma Inc. ZEVALIN ibritumomab tiuxetan Injection 125019 February 19, 2002 6,399,061 2015-06-07
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.